RFS was defined as the time span between the date of the first PD-1 inhibitor treatment and until recurrence of melanoma, or last scan without recurrence, determined by FDG-PET/CT scans using Response Evaluation Criteria in Solid Tumors (RECIST) [21]. Here, PDCD1 is linked to melanoma.